Most antidepressant drugs are safe for patients with epilepsy at therapeutic doses: A review of the evidence

Epilepsy and Behavior

Volumn 61, Issue , 2016, Pages 282-286

  Kanner, Andres M ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Animal models of epilepsy; Bupropion; Clomipramine; Focal epilepsy; Selective serotonin reuptake inhibitors; Serotonin norepinephrine reuptake inhibitors

Indexed keywords

5 HYDROXYTRYPTOPHAN; ANTIDEPRESSANT AGENT; BICUCULLINE; CARBAMAZEPINE; CITALOPRAM; DULOXETINE; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; LAMOTRIGINE; NORFLUOXETINE; OXCARBAZEPINE; PAROXETINE; PHENYTOIN; RUFINAMIDE; SEROTONIN 1A RECEPTOR; SERTRALINE; VALPROIC ACID; VENLAFAXINE; ZONISAMIDE; ANTICONVULSIVE AGENT; SEROTONIN UPTAKE INHIBITOR;

ANTICONVULSANT ACTIVITY; ANXIETY DISORDER; DIARRHEA; DISEASE ASSOCIATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG SAFETY; ELECTROSHOCK SEIZURE; ENZYME INHIBITION; EPILEPSY; EPILEPTIC STATE; FOCAL EPILEPSY; GENERALIZED EPILEPSY; HEADACHE; HUMAN; HYPERHIDROSIS; HYPERTENSION; HYPONATREMIA; INAPPROPRIATE VASOPRESSIN SECRETION; INSOMNIA; MAJOR DEPRESSION; NAUSEA; NONHUMAN; OBESITY; OSTEOPENIA; OSTEOPOROSIS; POSITRON EMISSION TOMOGRAPHY; PRESCRIPTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENCE RISK; REMISSION; REVIEW; SEXUAL DYSFUNCTION; TEMPORAL LOBE EPILEPSY; TONIC CLONIC SEIZURE; XEROSTOMIA; COMPLICATION; DEPRESSIVE DISORDER, MAJOR;

ANTICONVULSANTS; ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER, MAJOR; EPILEPSY; HUMANS; SEROTONIN UPTAKE INHIBITORS;

EID: 84969724176     PISSN: 15255050     EISSN: 15255069     Source Type: Journal    
DOI: 10.1016/j.yebeh.2016.03.022     Document Type: Review

References (58)

1. Tellez-Zenteno, J.F., Patten, S.B., Jetté, N., Williams, J., Wiebe, S., Psychiatric comorbidity in epilepsy: a population-based analysis. Epilepsia 48 (2007), 2336–2344.
2. Hamid, A., Kanner, A.M., Should antidepressant drugs of the selective serotonin reuptake inhibitor family be tested as antiepileptic drugs?. Epilepsy Behav 26:3 (2013), 261–265.
3. Jobe, P.C., Dailey, J.W., Wernicke, J.F., A noradrenergic and serotonergic hypothesis of the linkage between epilepsy and affective disorders. Crit Rev Neurobiol 13 (1999), 317–356.
4. Preskorn, S., Fast, G., Tricyclic antidepressant induced seizures and plasma drug concentration. J Clin Psychiatry 53 (1992), 160–162.
5. Rosenstein, D., Nelson, J., Jacobs, S., Seizures associated with antidepressants: a review. J Clin Psychiatry 54 (1993), 289–299.
6. Waring, W.S., Gray, J.A., Graham, A., Predictive factors for generalized seizures after deliberate citalopram overdose. Br J Clin Pharmacol 66:6 (2008), 861–865.
7. 1A receptors. J Neurochem 89 (2004), 834–843.
8. Forsgren, L., Nystrom, L., An incident case-referent study of epileptic seizures in adults. Epilepsy Res 6 (1990), 66–81.
9. Hesdorffer, D.C., Hauser, W.A., Annegers, J.F., Cascino, G., Major depression is a risk factor for seizures in older adults. Ann Neurol 47 (2000), 246–249.
10. Hesdorffer, D.C., Hauser, W.A., Ludvigsson, P., Olafsson, E., Kjartansson, O., Depression and attempted suicide as risk factors for incident unprovoked seizures and epilepsy. Ann Neurol 59 (2006), 35–41.
11. Hesdorffer, D.C., Ishihara, L., Mynepalli, L., Webb, D.J., Weil, J., Hauser, W.A., Epilepsy, suicidality, and psychiatric disorders: a bidirectional association. Ann Neurol 72 (2012), 184–191.
12. Lewis, A., Melancholia: a historical review. J Ment Sci 80 (1934), 1–42.
13. Jones, J.E., Bell, B., Fine, J., Rutecki, P., Seidenberg, M., Hermann, B., A controlled prospective investigation of psychiatric comorbidity in temporal lobe epilepsy. Epilepsia 48:12 (2007), 2357–2360.
14. Alper, K., Schwartz, K.A., Kolts, R.L., Khan, A., Seizure incidence in psychopharmacological clinical trials: an analysis of Food and Drug Administration (FDA) summary basis of approval reports. Biol Psychiatry 62:4 (2007), 345–354.
15. Barry, J., Ettinger, A.B., Harden, C.L., Gilliam, F., Kanner, A.M., Depression consensus statement. Epilepsy Behav(Suppl. 1), 2008, S1–29.
16. 1A receptor binding in patients with temporal lobe epilepsy. Neurology 60 (2003), 749–756.
17. 1A receptor binding in human temporal lobe epilepsy. Neurology 62 (2004), 1343–1351.
18. 18F]MPPF-PET study. Brain 127 (2004), 900–913.
19. Theodore, W.H., Giovacchini, G., Bonwetsch, R., Bagic, A., Reeves-Tyer, P., Herscovitch, P., et al. The effect of antiepileptic drugs on 5-HT-receptor binding measured by positron emission tomography. Epilepsia 47:3 (2006), 499–503.
20. Hasler, G., Bonwetsch, R., Giovacchini, G., Toczek, M.T., Bagic, A., Luckenbaugh, D.A., et al. 5-HT(1A) receptor binding in temporal lobe epilepsy patients with and without major depression. Biol Psychiatry 62:11 (2007), 1258–1264.
21. Meschaks, A., Lindstrom, P., Halldin, C., Farde, L., Savic, I., Regional reductions in serotonin 1A receptor binding in juvenile myoclonic epilepsy. Arch Neurol 62 (2005), 946–960.
22. Jobe, P.C., Picchioni, A.L., Chin, L., Role of brain 5-hydroxytryptamine in audiogenic seizure in the rat. Life Sci 13:1 (1973), 1–10.
23. Yan, Q.S., Jobe, P.C., Dailey, J.W., Evidence that a serotonergic mechanism is involved in the anticonvulsant effect of fluoxetine in genetically epilepsy-prone rats. Eur J Pharmacol 252:1 (1993), 105–112.
24. Yan, Q.S., Jobe, P.C., Dailey, J.W., Further evidence of anticonvulsant role for 5-hydroxytryptamine in genetically epilepsy prone rats. Br J Pharmacol 115 (1995), 1314–1318.
25. Mazarati, A., Siddarth, P., Baldwin, R.A., Shin, D., Caplan, R., Sankar, R., Depression after status epilepticus: behavioural and biochemical deficits and effects of fluoxetine. Brain 131:Pt 8 (2008), 2071–2083.
26. Prendiville, S., Gale, K., Anticonvulsant effect of fluoxetine on focally evoked limbic motor seizures in rats. Epilepsia 34:2 (1993), 381–384.
27. 1A receptor agonists modify seizures in three experimental models in rats. Neuropharmacology 49 (2005), 367–375.
28. 2 + dependent dopamine release. Epilepsy Res 13:2 (1992), 113–119.
29. Dailey, J.W., Yan, Q.S., Adams-Curtis, L.E., Ryu, J.R., Ko, K.H., Mishra, P.K., et al. Neurochemical correlates of antiepileptic drugs in the genetically epilepsy-prone rat (GEPR). Life Sci 58:4 (1996), 259–266.
30. Ahmad, S., Fowler, L.J., Whitton, P.S., Lamotrigine, carbamazepine and phenytoin differentially alter extracellular levels of 5-hydroxytryptamine, dopamine and amino acids. Epilepsy Res 63:2–3 (2005), 141–149.
31. Clinckers, R., Smolders, I., Meurs, A., Ebinger, G., Michotte, Y., Hippocampal dopamine and serotonin elevations as pharmacodynamic markers for the anticonvulsant efficacy of oxcarbazepine and 10,11-dihydro-10-hydroxicarbamazepine. Neurosci Lett 16:390 (2005), 48–53.
32. Clinckers, R., Smolders, I., Meurs, A., Ebinger, G., Michotte, Y., Quantitative in-vivo microdialysis study on the influence of multidrug transporters on the blood-brain barrier passage of oxcarbazepine: concomitant use of hippocampal monoamines as pharmacodynamic markers for the anticonvulsant activity. J Pharmacol Exp Ther 314 (2005), 725–731.
33. Dailey, J.W., Reith, M.E.A., Yan, Q.S., Li, M.Y., Jobe, P.C., Anticonvulsant doses of carbamazepine increase hippocampal extracellular serotonin in genetically epilepsy-prone rats: dose response relationships. Neurosci Lett 227:1 (1997), 13–16.
34. Dailey, J.W., Reith, M.E., Steidley, K.R., Milbrandt, J.C., Jobe, P.C., Carbamazepine-induced release of serotonin from rat hippocampus in vitro. Epilepsia 39:10 (1998), 1054–1063.
35. 2 +. Eur J Pharmacol 328:2–3 (1997), 153–162.
36. Southam, E., Kirkby, D., Higgins, G.A., Hagan, R.M., Lamotrigine inhibits monoamine uptake in vitro and modulates 5-hydroxytryptamine uptake in rats. Eur J Pharmacol 358:1 (1998), 19–24.
37. Whitton, P.S., Fowler, L.J., The effect of valproic acid on 5-hydroxytryptamine and 5-hydroxyindoleacetic acid concentration in hippocampal dialysates in vivo. Eur J Pharmacol 200 (1991), 167–169.
38. Beck, S.G., Choi, K.C., 5-Hydroxytryptamine hyperpolarizes CA3 hippocampal pyramidal cells through an increase in potassium conductance. Neurosci Lett 133 (1991), 93–96.
39. 1A receptor linked to inward-rectifying potassium current in hippocampal CA# pyramidal cells. J Neurophysiol 71 (1994), 2161–2167.
40. Sitges, M., Gómez, C.D., Aldana, B.I., Sertraline reduces IL-1β and TNF-α mRNA expression and overcomes their rise induced by seizures in the rat hippocampus. PLoS One, 9(11), 2014, e111665.
41. Bagdy, G., Kecskemeti, V., Riba, P., Jakus, R., Serotonin and epilepsy. J Neurochem 100:4 (2007), 857–873.
42. Kanner, A.M., Kozak, A.M., Frey, M., The use of sertraline in patients with epilepsy: is it safe?. Epilepsy Behav 1:2 (2000), 100–105.
43. Favale, E., Audenino, D., Cocito, L., Albano, C., The anticonvulsant effect of citalopram as an indirect evidence of serotonergic impairment in human epileptogenesis. Seizure 12 (2003), 316–318.
44. Favale, E., Rubino, V., Mainardi, P., Lunardi, G., Albano, C., Anticonvulsant effect of fluoxetine in humans. Neurology 45 (1995), 1926–1927.
45. Specchio, L.M., Iudice, A., Specchio, N., La Neve, A., Spinelli, A., Galli, R., et al. Citalopram as treatment of depression in patients with epilepsy. Clin Neuropharmacol 27 (2004), 133–136.
46. Blanchet, P., Frommer, G.P., Mood change preceding epileptic seizures. J Nerv Ment Dis 174 (1986), 471–476.
47. Kanner, A.M., Soto, A., Gross-Kanner, H., Prevalence and clinical characteristics of postictal psychiatric symptoms in partial epilepsy. Neurology 62 (2004), 708–713.
48. Weil, A., Depressive reactions associated with temporal lobe uncinate seizures. J Nerv Ment Dis 121 (1955), 505–510.
49. Hirschfield, R.M.A., Bowden, C.L., Gitlin, M.J., Keck, P.E., Suppes, T., Thase, M.E., et al. Practice guideline for the treatment of patients with bipolar disorder. Am J Psychiatry 159:Suppl. #4 (2002), 1–15.
50. Shelton, R.C., Lester, N., Selective serotonin reuptake inhibitors and newer antidepressants. Stein, D.J., Kupfer, D.J., Schatzberg, A.F., (eds.) Textbook of mood disorders, 2006, The American Psychiatric Publishing, Washington, DC, 263–280.
51. Stahl, S.M., Serotonin-norepinephrine reuptake inhibitors. Stahl, S.M., (eds.) Stahl's essential psychopharmacology, 3rd ed., 2008, Cambridge University Press, 541–552.
52. Patsalos, P., Perucca, E., Clinically important drug interactions in epilepsy: interactions between antiepileptic drugs and other drugs. Lancet Neurol 2 (2003), 473–481.
53. Trimble, M.R., Mula, M., Antiepileptic drug interactions in patients requiring psychiatric drug treatment. Majkowski, J., Bourgeois, B., Patsalos, P., Mattson, R., (eds.) Antiepileptic drugs. Combination therapy and interactions, 2005, Cambridge University Press, 350–368.
54. Nelson, M.H., Birnbaum, A.K., Remmel, R.P., Inhibition of phenytoin hydroxylation in human liver microsomes by several selective serotonin re-uptake inhibitors. Epilepsy Res 44 (2001), 71–82.
55. Haney, E.M., Warden, S.J., Bliziotes, M.M., Effects of selective serotonin reuptake inhibitors on bone health in adults: time for recommendations about screening, prevention and management?. Bone 46:1 (2010), 13–17.
56. Diem, S.J., Blackwell, T.L., Stone, K.L., Yaffe, K., Haney, E.M., Bliziotes, M.M., et al. Use of antidepressants and rates of hip bone loss in older women: the study of osteoporotic fractures. Arch Intern Med 167:12 (2007), 1240–1245.
57. Liu, B., Anderson, G., Mittmann, N., To, T., Axcell, T., Shear, N., Use of selective serotonin-reuptake inhibitors or tricyclic antidepressants and risk of hip fractures in elderly people. Lancet 351:9112 (1998), 1303–1307.
58. Warden, S.J., Robling, A.G., Sanders, M.S., Bliziotes, M.M., Turner, C.H., Inhibition of the serotonin (5-hydroxytryptamine) transporter reduces bone accrual during growth. Endocrinology 146 (2005), 685–693.